Home
Brain tumour immunology and therapy group

News archive for Brain tumour immunology and therapy group

Bortezomib as chemosensitizer for glioblastoma patients with unmethylated MGMT promoter: Phase IB/II clinical trial and mechanisms of therapeutic efficacy